Why is the Optune device not covered for this Quebec patient?

According to Le Journal de Montréal, both the provincial plan and the private insurer declined coverage in this case. Reasons were not detailed publicly. Denials can stem from questions about clinical criteria, evidence thresholds, or plan terms. Administrative reviews or new documentation can sometimes prompt a reassessment of eligibility.

How much does the Optune device cost in Canada?

The report cites C$31,000 per month out of pocket for the Quebec patient, which equates to about C$372,000 per year at that rate. Actual costs can vary by contract, duration, and supplies. Any negotiated discounts or patient assistance could change the net expense to families or plans.

What could this mean for Manulife insurance premiums?

If high‑cost device claims rise, Manulife insurance may adjust reserves and renewal pricing, especially for experience‑rated group plans. It could also add device sublimits, stricter prior authorization, or stop‑loss structures. The final impact depends on utilization, negotiated pricing, and how much risk moves into pooled protection versus employer‑specific coverage.

What should investors watch in the coming weeks?

Watch for Quebec policy reviews, administrative appeal outcomes, and insurer policy bulletins on device coverage. Look for employer plan amendments that cap medical equipment. Supplier updates about Canadian pricing or patient assistance also matter. Further Le Journal de Montréal reporting can signal shifting public pressure that often precedes formal changes.

Law and Government

February 22: Quebec Cancer Device Coverage Fight Puts Insurer Costs in Focus

ByDanny Kontos February 22, 2026February 22, 2026

Le Journal de Montréal reports a Quebec patient facing C$31,000 per month out of pocket for the Optune cancer device after denials from the province and Manulife. The case highlights Quebec health coverage gaps and rising med‑tech costs that could shift insurer expenses. At the reported rate, annual cost is about C$372,000, a level that can reshape benefit design and risk pooling. With public and private plans under scrutiny, the next decisions could influence device adoption, supplier negotiations, and premiums across Canada.